Ergeron-DS Tablet is a combination pharmaceutical formulation containing Bromelain (180 mg), Trypsin (96 mg), and Rutoside (200 mg), designed to provide anti-inflammatory, fibrinolytic, and vasoprotective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, exhibits anti-inflammatory and analgesic properties by modulating inflammatory mediators and promoting the breakdown of fibrin clots. Trypsin, a serine protease enzyme, complements this action by enhancing proteolytic activity, facilitating the reduction of edema and inflammation in acute and chronic inflammatory conditions. Rutoside, a bioflavonoid, contributes to vascular health through its antioxidant and capillary-strengthening effects, improving microcirculation and reducing capillary permeability. The synergistic action of these components makes Ergeron-DS effective in managing conditions such as post-traumatic inflammation, soft tissue injuries, and venous insufficiency. It is indicated for adjunctive therapy in inflammatory disorders where reduction of swelling, pain, and vascular fragility is desired. Ergeron-DS should be administered under medical supervision, with consideration of contraindications such as hypersensitivity to any component and caution in patients with bleeding disorders. The tablet formulation ensures convenient oral dosing, promoting patient compliance in therapeutic regimens aimed at inflammation and vascular protection.